论文部分内容阅读
目的探讨米非司酮在治疗绝经过渡期子宫肌瘤方面的疗效。方法对已确诊为绝经过渡期子宫肌瘤的患者,每日口服米非司酮12.5mg,连续6个月,观察治疗后子宫体积、内膜厚度,血清性激素水平,停药半年月经情况。结果用药后子宫体积变小,血FSH、LH、P激素水平下降,临床症状改善或基本消失,子宫内膜厚度均表现为早卵泡期内膜。结论米非司酮具有很强的非竞争性抗雌激素作用,阻碍增生的子宫内膜对生理雌激素的正常反应而使子宫内膜萎缩,出血减少。并减少子宫动脉血流量,使瘤体体积缩小,症状减轻。本研究在服用米非司酮对治疗绝经过渡期子宫肌瘤方面效果肯定,安全可行。
Objective To investigate the efficacy of mifepristone in the treatment of uterine fibroids in menopausal transitional period. Methods Patients with confirmed uterine fibroids in menopausal transitional period were given oral mifepristone 12.5 mg for 6 months continuously to observe the uterine volume, thickness of the intima, serum sex hormone level and menstruation after six months of treatment. Results After treatment, the uterus became smaller, the levels of FSH, LH and P decreased, and clinical symptoms improved or almost disappeared. The thickness of endometrium showed endometrium in early follicular phase. Conclusion Mifepristone has a strong non-competitive anti-estrogen effect, hinder the proliferation of endometrial normal physiological estrogen and endometrial atrophy, reduced bleeding. And reduce uterine artery blood flow, the tumor volume reduced, the symptoms alleviate. This study of mifepristone in the treatment of menopausal transitional uterine fibroids positive effect, safe and feasible.